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Several randomized studies (Clark et al, 1992; Veronesi et al,
1993; Liljegren et al, 1994; Fisher et al, 1995; Veronesi et al, 1995;
Forrest et al, 1996; Liljegren et al, 1996; Renton et al 1996) and a
meta-analysis (Early Breast Cancer Trialists Collaborative Group,
1995) have concluded that lumpectomy or quadrantectomy result
in survival rates similar to those in mastectomy in stage I and II
breast cancer, provided that adequate postoperative breast irradia-
tion using modern radiotherapy techniques is given subsequent to
breast preserving surgery. The main objective for postoperative
radiotherapy is to reduce the rate of locoregional recurrences. The
rate of ipsilateral breast recurrences has been reported to vary
between 9% and 35% in patients not receiving postoperative irra-
diation after breast-preserving surgery. Postoperative radiation
reduces the local recurrence rate to about one third (Kurtz et al,
1989; Clark et al, 1992; van Dongen et al, 1992, Veronesi et al,
1993; Liljegren et al, 1994; Early Breast Cancer Trialists
Collaborative Group, 1995; Fisher et al, 1995; Veronesi et al,
1995; Forrest et al, 1996; Liljegren et al, 1996; Renton et al 1996),
and it has reduced the risk of recurrence after breast-preserving
surgery in randomized studies regardless of whether tumours 2 cm
or smaller (Liljegren et al, 1999), tumours smaller than 2.5 cm
(Veronesi et al, 1993), or 4 cm or smaller in diameter (Clark et al,
1992; Fisher et al, 1995; Forrest et al, 1996) had been accrued, and
regardless of whether only invasive or purely intraductal cancers
were included in the studies (Fisher et al, 1998). 
There are at present no established clinical or biological factors
that reliably identify patients who could be spared from
postoperative radiotherapy after lumpectomy (Fourquet et al,
1989; Locker et al, 1989; Clarke and Martinez, 1992; Julien et al,
2000). The most important risk factors for local recurrence after
breast-preserving surgery are the width of the surgical margin and
the presence of an extensive intraductal component (EIC) (Kurtz,
1992; Gage et al, 1996; Sinn et al, 1998; Voogd et al, 1999) Gross
resection margins of 1 to 2 cm are generally considered necessary
(Gage et al, 1996; Renton et al, 1996), but in one study approx-
imately 30% of patients with EIC-positive cancers had prominent
residual intraductal carcinoma at least 2 cm beyond the edge of the
primary tumour, compared to only 2% of EIC-negative cancers
(Holland et al, 1990), suggesting that even a 2-cm margin may be
inadequate unless radiotherapy is given. The lowest local relapse
rates were seen in the QUART study where there was the most
extensive surgery (Veronesi et al, 1985). Although evidence
regarding other risk factors is more controversial, it has been
suggested that young age at presentation (Clark et al, 1992; Kurtz,
1992; de la Rochefordiere et al, 1993; Fowble et al, 1994), high
nuclear grade, high tumour proliferation rate, presence of vascular
invasion (Kurtz et al, 1990; Clark et al, 1992; Dalberg et al, 1999)
and multifocality predict local recurrence. 
Breast irradiation also has adverse effects such as an increased
risk of breast fibrosis and oedema, nipple retraction, teleangiec-
tasia and other skin changes, and impaired cosmesis, in particular
if large daily fractions or if total target doses higher than 50 Gy are
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Summary The aim of this trial was to study the value of adding post-operative radiotherapy to lumpectomy in a subgroup of breast
cancer patients with favourable patient-, tumour-, and treatment-related prognostic features. 152 women aged over 40 with unifocal breast
cancer seen in preoperative mammography were randomly assigned to lumpectomy alone (no-XRT group) or to lumpectomy followed by
radiotherapy to the ipsilateral breast (50 Gy given within 5 weeks, XRT group). All cancers were required to be invasive node-negative,
smaller than 2 cm in diameter and well or moderately differentiated, to contain no extensive intraductal component, to be progesterone
receptor-positive, DNA diploid, have S-phase fraction ≤7 and be excised with at least 1 cm margin. During a mean follow-up time of 6.7 years,
13 (18.1%) cancers recurred locally in the no-XRT and 6 (7.5%) in the XRT group (P = 0.03). There was no difference between the groups in
the ultimate breast preservation rate (95.0% vs. 94.4% in XRT and no-XRT, respectively, P = 0.88), distant metastasis-free survival (P = 0.36),
or 5-year cancer-specific survival (97.1% in XRT and 98.6 in no-XRT). Radiation therapy given after lumpectomy reduces the frequency of
ipsilateral breast recurrences even in women with small breast cancer with several favourable clinical and biological features. However, the
breast preservation rate may not increase due to more frequent use of salvage mastectomies in patients treated with postoperative
radiotherapy. © 2001 Cancer Research Campaign http://www.bjcancer.com
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given to the entire breast volume (de al Rochefordiere et al, 1992).
Postoperative radiotherapy also increases the economic cost of
treatment. If therefore recurrence rates were similar between
radiotherapy and no-radiotherapy groups, radiation should be
avoided. We hypothetized that if breast-conserving surgery is
based on standardized surgical procedures and carried out by a
small team of trained breast cancer surgeons, and if only small and
biologically non-aggressive cancers are selected for lumpectomy,
the rate of breast cancer recurrence might remain low even without
postoperative radiotherapy. Here we report the results of a
randomized trial in this selected breast cancer subgroup, where the
patients were randomly assigned either to postoperative radio-
therapy (XRT) or to no radiotherapy (no-XRT) after mammo-
graphy and lumpectomy. The estimation of tumour-biologic
aggressiveness was based on a combination of several prognostic
features often considered to be favourable. To our knowledge, in
all randomized studies reported so far patient selection for breast-
preserving therapy has been primarily based on tumour size and
not on factors related to tumour-biological aggressiveness, which
might be a relevant approach in view of the tumour tendency to
recur locally. 
MATERIALS AND METHODS 
Patients 
All conservatively operated female patients with invasive breast
cancer treated in the Tampere University Hospital District between
May 1990 and May 1995 were counseled by an oncologist 3 to 6
weeks after surgery. After counseling and informed consent,
patients who were considered to have breast cancer with a low risk
of recurrence were randomly assigned either to receive or not to
receive postoperative radiotherapy. All patients had a mammo-
gram taken preoperatively. Low risk of recurrence was strictly
defined, and for study accrual all patient-related, tumour-related
and treatment-related factors were to be fulfilled. Age at random-
ization was to be over 40, and patients with axillary nodal or
distant metastases at presentation were excluded. The greatest
diameter of the tumour measured microscopically was required to
be smaller than 20 mm, histological grade either I (well differenti-
ated) or II (moderately differentiated), progesterone receptor status
positive, no extensive intraductal component (EIC) present,
nuclear DNA content diploid as determined by DNA flow cytom-
etry, the S-phase fraction low (≤7%), and the tumour unifocal in
preoperative mammography. The resection margins were required
to be free of cancer with at least 1 cm healthy breast tissue between
cancer and resection margin under light microscopy. The type of
surgery to be carried out was lumpectomy with axillary dissection.
If the tumour size was too small to allow sampling for hormone
receptor and flow cytometric DNA content assays (usually less
than 5 mm, 10% of cases), histologic grade I or II was considered
sufficient evidence for low biological aggressiveness (Table 1). 
Breast surgery 
Segmental resection and axillary dissection were carried out
according to standardized procedures. 93% of all breast cancer
surgery undertaken was performed by 4 surgeons. The mammary
gland was dissected free in the plane of Scapa’s fascia down to the
pectoral muscle. The pectoral fascia was included in the removed
specimen. Lumpectomy was effected with bi-digital control of the
palpable or localized tumours. Non-palpable tumours were local-
ized with radiological wire-hook marking. The resection specimen
was removed with at least 1 cm gross tumour-free margins
measured by pathologist. A level I and level II lymph node dissec-
tion was performed through a separate axillary incision. 
Randomization 
Randomization was applied 3 to 8 weeks after surgery. After
obtaining informed consent, assignment to the treatment groups
was carried out by a phone call to the secretary, located at the
Department of Oncology. The participant’s name and social secur-
ity number, comprising date of birth and an individual identifica-
tion code, was provided for unequivocal identification.
Randomization between the 2 arms was carried out by a computer
program generating random digits. No stratification was done. 
Postoperative radiotherapy and concomitant therapy 
In the group assigned to postoperative radiotherapy, this was
started within a few days after randomization and within 4 to 8
weeks after surgery. Radiotherapy was given by linear accelerator
using 2 opposed tangential fields with 5 MeV photons. The total
radiation dose was 50 Gy given within 5 weeks and in 2-Gy daily
fractions. The dose was specified at the International Commission
on Radiation Units and Measurements (IRCU) reference point
located at the intersection point of the 2 opposing beams within the
planning target volume, which comprised the entire ipsilateral
breast volume and the underlying chest wall but not the regional
axillary lymph nodes. Dose inhomogeneity within the target
volume was below 10%. No booster dose was given to the tumour
site. 
None of the patients received adjuvant endocrine therapy or
chemotherapy. Any medication considered necessary for treatment
of diseases other than breast cancer was allowed. 
Ethical considerations 
The study protocol was accepted by the Ethical Committee of the
hospital, and written informed consent was required before
accrual. 
Follow-up 
All patients were regularly followed up at the out-patient depart-
ment of the hospital. None was lost from follow-up. The follow-up
visits took place every 3 months during the first year after random-
ization, every 4 months during the second year, and every 6
months thereafter. At study closure in April 30th 1999, the mean
follow-up time for patients still alive was 6.7 years (range, 3.8 to
9.2 years). Clinical examination was made of the breasts and blood
chemistry analysed at every follow-up visit; mammography was
performed at 1-to-2-year intervals. 
Statistical analysis 
Survival was calculated from the date of surgery to death or the
last day of follow-up for those patients still alive. Time to locore-
gional progression was defined as the time from operation
until cancer was found in the ipsilateral breast or the regional
lymph nodes, and time to distant progression as the time fromrandomization to the appearance of metastases outside the loco-
regional area. Cancer-specific survival was obtained by censoring
deaths from intercurrent causes. Survival times were examined by
the Kaplan-Meier product-limit method, and survival between the
treatment arms was compared using log-rank test. Frequency
tables were analysed using the chi-square test with continuity
correction factor or Fisher’s exact test. All P values were 2-tailed. 
RESULTS 
A total of 152 patients were enrolled for the study, of whom 80
were assigned to receive post-lumpectomy radiotherapy and 72 to
no further therapy. One patient randomized to receive radiotherapy
refused treatment and was excluded. The two arms were well
balanced, and there were no differences between the treatment
groups in respect of age at diagnosis, cancer histological type or
grade, tumour size or S-phase fraction size (Table 2). There was no
association of age at diagnosis (P = 0.58) or tumour size (P =
0.95), histologic type (P = 0.94) or histologic grade (P = 0.96)
with the local recurrence rate in the series (Table 3). 
19 (12.5%) ipsilateral recurrences were diagnosed during
follow-up. 13 (18.1%) of these were found in the no-radiotherapy
group, and 6 (7.5%) in the radiotherapy group. The 5-year loco-
regional disease-free survival was 93.7% when postoperative
radiotherapy was given and 85.9% when not (P = 0.03) (Figure 1).
All locoregional recurrences were located in the preserved
ipsilateral breast. After recurrence, mastectomy was carried out in
4 (31%) of the 13 cases of locoregional recurrence in the no-radio-
therapy group and a re-resection was done in the remaining 9. In
the radiotherapy group 4 (67%) of the 6 recurrences were treated
with mastectomy and only 2 with re-resection (P = 0.32).
Radiotherapy was given after re-resection to patients randomized
to the no-radiotherapy group. Hence, the breast preservation rate
was almost identical in the two groups, 76 (95.0%) out of 80 in the
radiotherapy group and 68 (94.4%) out of 72 in the no-radio-
therapy group, (P = 0.88). 
Distant metastases were found in only 9 (5.9%) patients, in 7
(8,8%) patients who received postoperative radiotherapy and in 2
(2.8%) of those who did not (P = 0.41) (Fig. 2). When recurrence-
free survival (RFS) was computed taking into account both loco-
regional and distant recurrences, no significant difference in
recurrence-free survival was found between the groups. The
5-year RFS was 86.1% for patients in the radiotherapy group and
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Table 1 Inclusion criteria for the study 
Category Parameter 
Patient-related Age at randomization >40 
Tumour-related No axillary nodal metastases (pN0) 
No distant metastases (M0) 
Primary tumour size <2 cm 
No extensive intraductal component (EIC-) 
No multicentricity or multifocality in preoperative 
mammogram 
Histological grade I or II 
Progesterone receptor (PgR) positive 
If tumour size <5 mm, histological grade I or II 
Treatment-related Lumpectomy and axillary dissection performed 
Microscopical tumour-free margin 1 cm or
greater 
Table 2 Patient and tumour characteristics 
Parameter Radiation Controls  (-) 
therapy (n = 72)
(n = 80)
Median age at diagnosis (range) 54 (42–73) 56 (40–76) 
Primary tumour size (mm) 
≤ 59 9  
6–10 21 22 
10–15 29 32 
16–20 13 17 
Histological type (n) 
ductal 65 51 
lobular 6 10 
special 9 11 
Histological grade (n) 
grade I 52 52 
grade II 10 19 
not specified 10 9 
Median S-phase fraction (%) 4.0 (1.0–7.9) 4.0 (1.0–7.9) 
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Figure 1 Locoregional disease-free survival among 152 patients with 
low-risk breast cancer randomized either to postoperative radiotherapy (solid
line, n = 80) or to no further therapy (dashed line, n = 72) after lumpectomy 
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Figure 2 Distant disease-free survival. Solid line, postoperative
radiotherapy given; dashed line, no postoperative radiotherapy 84.4% for those not receiving postoperative radiotherapy,
(P = 0.36) (Fig. 3). Only 4 (2.6%) patients died of breast cancer
during follow-up (2 in either group), thus resulting in a 5-year
cancer-specific survival rate as high as 97.1% in the XRT group
and 98.6% in no-XRT (Fig. 4). 
DISCUSSION 
In this single-centre trial based on a geographically well-defined
population, emphasis was placed on minimizing patient-related,
tumour-related and treatment-related risk factors for breast cancer
recurrence to justify the omission of postoperative radiation
therapy after lumpectomy. We excluded young patients from the
trial, because young age has been considered a risk factor for local
recurrence (de la Rochefordiere et al, 1993; Fowble et al, 1994),
and selected for the study cancers of presumably low biological
aggressiveness, as judged from a panel of commonly used progno-
stic factors. The great majority (93%) of all cancers were treated
by only 4 surgeons, and we required at least 1 cm microscopically
healthy tissue margin and preoperative mammography for study
inclusion. In spite of these measures, lumpectomy without post-
operative radiotherapy was associated with an increased cancer
recurrence rate in the ipsilateral breast as compared with lumpec-
tomy followed by postoperative radiotherapy. However, breast
preservation, recurrence-free survival, and overall survival rates
were similar and excellent in both study groups during a mean
follow-up time of 6.7 years. 
The 5-year cancer-specific survival rate in the present series was
as high as 98%, suggesting that we were successful in selecting
cancers of low biological aggressiveness. Despite this, the overall
locoregional recurrence rate was 18.1% in the no-radiotherapy
cohort, much higher than the 7.5% in the radiotherapy group.
These figures do not appear to be different from those found in
series where patients were selected for breast-conserving therapy
primarily on the basis of tumour size (Fisher et al, 1995; Liljegren
et al, 1999), suggesting that the biological factors which predict
survival may not work equally well in the prediction of local recur-
rence. 
There was no difference between the groups in the breast preser-
vation rate. Recurrent or second ipsilateral breast cancers in
patients randomly allocated to radiotherapy were usually treated
with mastectomy, whereas the converse was the case in the no-
radiotherapy group. The option for post-lumpectomy radiotherapy
was still available for patients who had not received postoperative
radiotherapy after lumpectomy, and treatment of recurrent or
second cancer with limited surgery and irradiation balanced out
the increased number of local breast cancer recurrences detected in
the no-radiotherapy arm, resulting in a similar breast preservation
rate in both treatment groups. Recurrent tumours may also be more
difficult to diagnose early in the more dense and more fibrotic irr-
adiated breast tissue than in the unirradiated breast, this possibly
leading to larger tumour size at diagnosis and more often to
mastectomy (Kearney and Morrow, 1995). 
Although the mastectomy rates were similar in the two groups,
the possible adverse prognostic influence of local recurrence and
the resulting psychological distress should not be underestimated.
In the present series with low-malignancy tumours the increased
local relapse rate did not result in reduced cancer-specific or recur-
rence-free survival. On the other hand, distant metastases were
more common in the radiotherapy group. The number of cases is,
however, was too small to allow any firm conclusions. In a multi-
variate analysis from the National Surgical Adjuvant Breast and
Bowel Project (NSABP) study B-06, which compared mastec-
tomy, lumpectomy without irradiation, and lumpectomy with irra-
diation in the treatment of breast cancers 4 cm or less in diameter,
the findings indicated that local recurrence is associated with a 3-
fold increased relative risk of distant metastases, even when other
prognostic factors are also considered (Fisher et al, 1991). Similar
findings have been reported by others (Whelan et al, 1994). 
Although the majority of patients receiving post-lumpectomy
radiation therapy have good cosmetic outcome when treated by
modern radiation therapy techniques (Dalberg et al, 1999), the
therapy may contribute to breast fibrosis and cause nipple retrac-
tion. Thus omission of radiotherapy through careful patient
selection might improve the cosmetic outcome. Omission of radia-
tion therapy would significantly reduce the total cost of therapy. In
the present series only 12.5% of the patients randomly assigned to
the no-radiotherapy arm ever received radiotherapy, as compared
to 100% of those who were randomized to the postoperative radio-
therapy arm. However, no formal cost analysis was carried out,
Lumpectomy for breast cancer 167
British Journal of Cancer (2001) 84(2), 164–169 © 2001 Cancer Research Campaign
All recurrences
0
50
60
70
80
90
100
12
Follow-up (months)
P = 0.36
R
e
c
u
r
r
e
n
c
e
-
f
r
e
e
(
%
)
24 36 48 60 72 84
radiotherapy
no radiotherapy
Figure 3 Recurrence-free survival. Solid line, postoperative radiotherapy
given; dashed line, no postoperative radiotherapy 
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Figure 4 Cancer-specific survival. Solid line, postoperative radiotherapy
given; dashed line, no postoperative radiotherapy and treatment of recurrences is associated with further costs in
addition to those related to radiation therapy. 
In summary, post-lumpectomy radiation therapy reduces the
frequency of ipsilateral breast cancer recurrences even in women
who have small (< 2 cm in diameter) node-negative breast cancer
with several favourable prognostic features, and when the cancer
has been removed with at least 1 cm margin. However, we
obtained no evidence suggesting that postoperative radiotherapy
improved the breast preservation rate or survival in this selected
subgroup of patients. Commonly used prognostic factors may not
be efficient in predicting the tendency of breast cancer to recur
locally. Further studies using novel biological factors and new
breast imaging techniques and aiming at identifying subgroups of
breast cancer patients with a small risk of local recurrence after
breast-preserving surgery are highly warranted. 
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